Russia turns table on US, UK: 'Show study of your vaccines' safety' | Global News

Russia turns table on US, UK: ‘Show study of your vaccines’ safety’

/ 12:35 PM September 07, 2020

MANILA, Philippines — The head of the Russian Direct Investment Fund (RDIF) financing Russia’s vaccine project, which is set to start clinical trials with the Philippines, has challenged the US and the UK to come out with a study showing that their respective potential vaccines against the coronavirus have no long-term effects.

Russia’s development of a potential coronavirus vaccine has been “attacked by lots of Western media” RIDF chief executive officer Kirill Dmitriev said in an interview over ABS-CBN News Channel on Monday.

But Dmitriev cited the “great results” of a study recently published in Britain’s Lancet medical journal, which showed that patients in early tests developed antibodies with “no serious adverse events.”

Article continues after this advertisement

“I think it’s very important that the same standards applied to Russia [should be applied] to other countries…We answered all your questions, we published our data in a Western magazine, please show us your studies that show that monkey adenovirus vaccine such as AstraZenica’s British vaccine and MRNA, the US vaccine, have no long terms effects or increasing risk for cancer and infertility,” Dmitriev said.

FEATURED STORIES

“To our knowledge, those studies do not exist and this is very important… They need to show to their people how do they make sure that there is no high risk of cancer, no high risks of infertility,” he added.

He further said that Russia’s vaccine is “based on an already proven approach that has been tried by many people, including the US military,” in contrast to that of the US and the UK which he claimed “have not been studied long term.”

Article continues after this advertisement

“Russia took already its registered vaccine for Ebola that went through all the clinical trials: Phase 1, Phase 2, Phase 3 and just modified it a little bit to make this vaccine,” Dmitriev said.

Article continues after this advertisement

According to Dmitriev, Russia will apply for the pre-qualification process of the World Health Organization (WHO).

Article continues after this advertisement

Russia’s health ministry has already furnished WHO with the results of Moscow’s vaccine trial, he said.

“We’’ll be working with WHO…with all of the Western organizations. We are in touch with all the people who really care about the vaccine being available to lots of countries,” he added.

Article continues after this advertisement

The Philippines is scheduled to conduct Phase 3 of clinical trials of Sputnik V vaccine from October 2020 to March 2021.

The human testing phase will be funded by the Russian government and will be done simultaneously in Manila and Moscow.

Before trials start, however, vaccine experts in the country must first review the protocols and guidelines. This must also be approved by the Food and Drug Administration.

“We are very eager to start our clinical trials in the Philippines,” Dmitriev said.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

“We are in touch with your health ministry and once again, we agree that this issue should not be politicized. We should all be working together,” he added.

EDV

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: coronavirus pandemic, COVID-19 vaccine, Features, nation, RDIF, Russia vaccine, Russian Direct Investment Fund

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.